Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines

References

• Badie B, Goh C S, Klaver J, Herweijer H, Boothman D A. Combined radiation and p53 gene therapy of malignant glioma cells. Cancer Gene Therapy 1999; 6: 155–162
   PubMed Web of Science ®Google Scholar
• Bower M, Newlands E S, Bleehen N M, Brada M, Begent R J, Calvert H, Colquhoun I, Lewis P, Brampton M H. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemotherapy Pharmacology 1997; 40: 484–488
   PubMed Web of Science ®Google Scholar
• Ceccotti S, Dogliotti E, Gannon J, Karran P, Bignami M. O6-methylguanine in DNA inhibits replication in vitro by human cell extracts. Biochemistry 1993; 32: 13664–13672
   PubMedGoogle Scholar
• Combs S E, Gutwein S, Schulz-Ertner D, van Kampen M, Thilmann C, Edler L, Wannenmacher M M, Debus J. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlentherapie und Onkologie 2005; 181: 372–377
   PubMed Web of Science ®Google Scholar
• Combs S E, Schulz-Ertner D, Roth W, Herold-Mende C, Debus J, Weber K J. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. International Journal of Radiation Biology Physics 2007; 68: 873–882
   PubMed Web of Science ®Google Scholar
• Combs S E, Wagner J, Bischof M, Welzel T, Edler L, Rausch R, Wagner F, Bois A Z, Debus J, Schulz-Ertner D. Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. International Journal of Radiation Biology Physics 2008; 71: 999–1005
   PubMed Web of Science ®Google Scholar
• Elsässer T h, Scholz M. Cluster effects within the Local Effect Model. Radiation Research 2007; 167: 319–329
   PubMedGoogle Scholar
• Estlin E J, Lashford L, Ablett S, Price L, Gowing R, Gholkar A, Kohler J, Lewis I J, Morland B, Pinkerton C R, Stevens M C, Mott M, Stevens R, Newell D R, Walker D, Dicks-Mireaux C, McDowell H, Reidenberg P, Statkevich P, Marco A, Batra V, Dugan M, Pearson A D. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. British Journal of Cancer 1998; 78: 652–661
   PubMed Web of Science ®Google Scholar
• Haberer T, Becher W, Schardt D, Kraft G. Magnetic scanning system for heavy ion therapy. Nuclear Instruments & Methods in Physics Research Section A-Accelerators Spectrometers Detectors and Associated Equipment 1993; 330: 296–305
   Web of Science ®Google Scholar
• Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. Journal of Neurochemistry 2006; 96: 766–776
   PubMed Web of Science ®Google Scholar
• Hirose Y, Berger M S, Pieper R O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Research 2001; 61: 1957–1963
   PubMed Web of Science ®Google Scholar
• Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens A C, Van Meir E G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathology 1999; 9: 469–479
   PubMed Web of Science ®Google Scholar
• Iwadate Y, Mizoe J, Osaka Y, Yamaura A, Tsujii H. High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53. International Journal of Radiation Biology Physics 2001; 50: 803–808
   PubMed Web of Science ®Google Scholar
• Jakel O, Kramer M, Karger C P, Debus J. Treatment planning for heavy ion radiotherapy: Clinical implementation and application. Physics in Medicine and Biology 2001; 46: 1101–1116
   PubMed Web of Science ®Google Scholar
• Karran P, Bignami M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Research 1992; 20: 2933–2940
   PubMed Web of Science ®Google Scholar
• Karran P, Macpherson P, Ceccotti S, Dogliotti E, Griffin S, Bignami M. O6-methylguanine residues elicit DNA repair synthesis by human cell extracts. Journal of Biological Chemistry 1993; 268: 15878–15886
   PubMed Web of Science ®Google Scholar
• Kataoka Y, Murley J S, Patel R, Grdina D J. Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines. International Journal of Radiation Biology 2000; 76: 633–639
   PubMedGoogle Scholar
• Kitabayashi H, Shimada H, Yamada S, Yasuda S, Kamata T, Ando K, Tsujii H, Ochiai T. Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation. Oncology Report 2006; 15: 913–918
   PubMed Web of Science ®Google Scholar
• Kraft-Weyrather W, Kraft G, Ritter S, Scholz M, Stanton J A. The preparation of biological targets for heavy-ion experiments up to 20 MeV/u. Nuclear Instruments and Methods in Physics Research A 1989; 282: 22–27
   Google Scholar
• Kramer M. Treatment planning for heavy-ion radiotherapy: biological optimization of multiple beam ports. Journal of Radiation Research (Tokyo) 2001; 42: 39–46
   PubMed Web of Science ®Google Scholar
• Kramer M, Scholz M. Treatment planning for heavy-ion radiotherapy: Calculation and optimization of biologically effective dose. Physics in Medicine and Biology 2000; 45: 3319–3330
   PubMed Web of Science ®Google Scholar
• Liu L, Markowitz S, Gerson S L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Research 1996; 56: 5375–5379
   PubMed Web of Science ®Google Scholar
• Mizoe J, Tsujii H, Hasegawa A, Takagi R, Yanagi T, Takakura K (2005) Carbon ion radiotherapy for malignant gliomas. Abstracts from the World Federation of Neuro-Oncology Meeting, EdinburghUK, May, 2005, Abstract 421
   Google Scholar
• Newlands E S, Blackledge G R, Slack J A, Rustin G J, Smith D B, Stuart N S, Quarterman C P, Hoffman R, Stevens M F, Brampton M H. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). British Journal of Cancer 1992; 65: 287–291
   PubMed Web of Science ®Google Scholar
• Newlands E S, O'Reilly S M, Glaser M G, Bower M, Evans H, Brock C, Brampton M H, Colquhoun I, Lewis P, Rice-Edwards J M, Illingworth R D, Richards P G. The Charing Cross Hospital experience with temozolomide in patients with gliomas. European Journal of Cancer 1996; 32A: 2236–2241
   PubMed Web of Science ®Google Scholar
• O'Reilly S M, Newlands E S, Glaser M G, Brampton M, Rice-Edwards J M, Illingworth R D, Richards P G, Kennard C, Colquhoun I R, Lewis P. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. European Journal of Cancer 1993; 29A: 940–942
   PubMed Web of Science ®Google Scholar
• Pegg A E, Dolan M E, Moschel R C. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Progress in Nucleic Research and Molecular Biology 1995; 51: 167–223
   PubMed Web of Science ®Google Scholar
• Pera M F, Koberle B, Masters J R. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. British Journal of Cancer 1995; 71: 904–906
   PubMed Web of Science ®Google Scholar
• Radford I R, Hodgson G S. Effect of ploidy on the response of V79 cells to ionizing radiation. International Journal of Radiation Biology & Related Studies in Physics, Chemistry & Medicine 1987; 51: 765–778
   PubMed Web of Science ®Google Scholar
• Reid J M, Stevens D C, Rubin J, Ames M M. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clinical Cancer Research 1997; 3: 2393–2398
   PubMed Web of Science ®Google Scholar
• Scholz M, Kellerer A M, Kraft-Weyrather W, Kraft G. Computation of cell survival in heavy ion beams for. The model and its approximation. Radiation and Environmental Biophysics 1997; 36: 59–66
   PubMed Web of Science ®Google Scholar
• Schulz-Ertner D, Karger C P, Feuerhake A, Nikoghosyan A, Combs S E, Jakel O, Edler L, Scholz M, Debus J. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. International Journal of Radiation Biology Physics 2007a; 68: 449–457
   PubMed Web of Science ®Google Scholar
• Schulz-Ertner D, Nikoghosyan A, Didinger B, Munter M, Jakel O, Karger C P, Debus J. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 2005; 104: 338–344
   PubMed Web of Science ®Google Scholar
• Schulz-Ertner D, Nikoghosyan A, Hof H, Didinger B, Combs S E, Jakel O, Karger C P, Edler L, Debus J. Carbon ion radiotherapy of skull base chondrosarcomas. International Journal of Radiation Biology Physics 2007b; 67: 171–177
   PubMed Web of Science ®Google Scholar
• Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. Journal of Clinical Oncology 2007; 25: 953–964
   PubMed Web of Science ®Google Scholar
• Schwartz J L. The radiosensitivity of the chromosomes of the cells of human squamous cell carcinoma cell lines. Radiation Research 1992; 129: 96–101
   PubMed Web of Science ®Google Scholar
• Stevens M F, Hickman J A, Langdon S P, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson N W, Slack J A. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Research 1987; 47: 5846–5852
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason W P, Van den Bent M J, Weller M, Fisher B, Taphoorn M J, Belanger K, Brandes A A, Marosi C, Bogdahn U, Curschmann J, Janzer R C, Ludwin S K, Gorlia T, Allgeier A, Lacombe D, Cairncross J G, Eisenhauer E, Mirimanoff R O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005; 352: 987–996
   PubMed Web of Science ®Google Scholar
• Suzuki M, Kase Y, Yamaguchi H, Kanai T, Ando K. Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon-ion beams. International Journal of Radiation Biology Physics 2000; 48: 241–250
   PubMed Web of Science ®Google Scholar
• Till J E. Radiosensitivity and chromosome numbers in strain L mouse cells in tissue culture. Radiation Research 1961; 15: 400–409
   PubMed Web of Science ®Google Scholar
• Tsuboi K, Moritake T, Tsuchida Y, Tokuuye K, Matsumura A, Ando K. Cell cycle checkpoint and apoptosis induction in glioblastoma cells and fibroblasts irradiated with carbon beam. Journal of Radiation Research (Tokyo) 2007; 48: 317–325
   PubMed Web of Science ®Google Scholar
• van Rijn J, Heimans J J, van den Berg J, van der Valk P, Slotman B J. Survival of human glioma cells treated with various combinations of temozolomide and X-rays. International Journal of Radiation Biology Physics 2000; 47: 779–784
   PubMed Web of Science ®Google Scholar
• Walker M D, Green S B, Byar D P, Alexander E, Jr, Batzdorf U, Brooks W H, Hunt W E, MacCarty C S, Mahaley M S, Jr, Mealey J, Jr, Owens G, Ransohoff J, Robertson J T, Shapiro W R, Smith K R, Jr, Wilson C B, Strike T A. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New England Journal of Medicine 1980; 303: 1323–1329
   PubMed Web of Science ®Google Scholar
• Walker M D, Strike T A, Sheline G E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. International Journal of Radiation Biology Physics 1979; 5: 1725–1731
   PubMed Web of Science ®Google Scholar
• Wedge S R, Porteous J K, Glaser M G, Marcus K, Newlands E S. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 1997; 8: 92–97
   PubMed Web of Science ®Google Scholar
• Weyrather W K, Ritter S, Scholz M, Kraft G. RBE for carbon track-segment irradiation in cell lines of differing repair capacity. International Journal of Radiation Biology 1999; 75: 1357–1364
   PubMed Web of Science ®Google Scholar
• Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003; 22: 8233–8245
   PubMed Web of Science ®Google Scholar